Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Tavares, Marcelo de Sousa
- Bone Mineral Disease and Kidney Transplantation in Children and Adolescents
Abstract Views :253 |
PDF Views:0
Authors
Affiliations
1 Pediatric Nephrology Unit, Room 267 Federal University of Minas Gerais, School of Medicine Department of Pediatrics, Pediatric Nephrology Unit Belo Horizonte, Minas Gerais, BR
2 Pediatric Nephrology Unit, School of Medicine, Federal University of Minas Gerais, BR
1 Pediatric Nephrology Unit, Room 267 Federal University of Minas Gerais, School of Medicine Department of Pediatrics, Pediatric Nephrology Unit Belo Horizonte, Minas Gerais, BR
2 Pediatric Nephrology Unit, School of Medicine, Federal University of Minas Gerais, BR
Source
Journal of Clinical Pediatric Nephrology, Vol 2, No 2 (2013), Pagination: 38-46Abstract
This review highlights the recent advances in the pathophysiology of bone mineral disease after kidney transplantation in children and adolescents. The observed hypophosphatemia during the first months are due to the high levels of FGF-23 in most patients. The first year posttransplantation is characterized by a loss of bone mineral density, from which the patient may recover after 1-5 years. Genetic and molecular mechanisms that affect the bone microenvironment, as the role of RANK/RANK-L, FGF-23 and osteoprotegerin as well as effects of immunosuppressive drugs are summarized. Immunosuppressive drugs may also induce adynamic bone disease and bone evaluation through bone densitometry is recommended in many studies, but its use in transplanted children is limited. There is insufficient evidence to recommend specific treatments for post-transplant renal bone disease in children, despite promising results in adult patients treated with anti-resorptive therapy. Guidelines regarding practical clinical approach of pediatric kidney recipients, such as from KDIGO and KDOQI are discussed. Prompt recognition of risk factors for bone mineral disease after kidney Tx should be a major goal for those who care for pediatric transplant recipients.Keywords
Adolescents, Bone, Children, Kidney TransplantationReferences
- Saland, J. M. Osseous complications of pediatric transplantation. Pediatr Transplant 2004; 8(4): 400-15.
- Mussa A, Porta F, Gianoglio B, Gaido M, Nicolosi M G, De Terlizzi F, de Sanctis C, Coppo R. Bone alterations in children and young adults with renal transplant assessed by phalangeal quantitative ultrasound. Am J Kidney Dis 2007; 50(3): 441-9.
- Feber J, Cochat P, Braillon P, Castelo F, Martin X, Glastre C, Chapuis F, David L, Meunier PJ. Bone mineral density after renal transplantation in children. J Pediatr. 1994 Dec;125(6 Pt 1):870- 5.
- Valta H, Makitie O, Ronnholm K, Jalanko H. Bone health in children and adolescents after renal transplantation. 2009; J Bone Miner Res 24(10):1699-708.
- Reddy SV. Regulatory mechanisms operative in osteoclasts. Crit Rev Eukaryot Gene Expr 2004;14 (4):255-70.
- Terpstra AM, Kalkwarf HJ, Shults J, Zemel BS, Wetzsteon RJ, Foster BJ, Strife CF, Foerster DL, Leonard MB. Bone density and cortical structure after pediatric renal transplantation. J Am Soc Nephrol 2012 Apr;23(4):715-26.
- Cao JJ. Effects of obesity on bone metabolism. J Orthop Surg Res 2011 Jun 15;6:30.
- Chen D, Zhang X, Guo Y, Shi S, Mao X, Pan X,Cheng T. MMP-9 inhibition suppresses wear debris-induced inflammatory osteolysis through downregulation of RANK/RANKL in a murine osteolysis model. Int J Mol Med. 2012 Dec; 30(6):1417-23.
- Mazanowska O, Kamiñska D, Krajewska M, Zabiñska M, Kopeæ W, Boratyñska M,Chudoba P, Patrzalek D, Klinger M. Imbalance of metalloproteinase/tissue inhibitors of metalloproteinase system in renal transplant recipients with chronic allograft injury.Transplant Proc. 2011 Oct; 43(8):3000-3.
- Casado-Díaz A, Santiago-Mora R, Dorado G, Quesada-Gómez JM. The omega-6 arachidonic fatty acid, but not the omega-3 fatty acids, inhibits osteoblastogenesis and induces adipogenesis of human mesenchymal stem cells: Potential implication in osteoporosis. Osteoporos Int. 2012 Oct 27 [Epub ahead of print].
- van Husen M, Lehnhardt A, Fischer A-K, Brinkert F, Loos S, Oh J, Kemper MJ. Fibroblast growth factor 23 and calcium phosphate homeostasis after pediatric renal transplantation. Pediatr Transplantation 2012: 16: 443–450.
- Evenpoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y. Tertiary ‘‘hyperphosphatoninism’’ accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007: 7: 1193–1200.
- Evenepoel P, Meijers BK, De Jonge H, et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 2008: 3: 1829–1836.
- Kanaan N,Claes K, Devogelaer JP, Vanderschueren D, Depresseux G, Goffin E, Evenepoel P. Fibroblast growth factor- 23 and parathyroid hormone are associated with post-transplant bone mineral density loss. Clin J Am Soc Nephrol 2010 Oct 5(10):1887-92.
- Wesseling-Perry K, Tsai EW, Ettenger RB, Jüppner H, Salusky IB. Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: A role for FGF-23? Nephrol Dial Transplant 2011 Nov; 26 (11):3779-84.
- Stein DR, Feldman HA, Gordon CM. Vitamin D status in children with chronic kidney disease. Pediatr Nephrol 2012 Aug 27(8):1341-50.
- Brodersen LA,Nielsen PR,Thiesson HC, Marckmann P. Vitamin D status in children and adolescents with kidney transplants. Pediatr Transplant 2011 Jun;15(4):384-9.
- Bienaimé F, Girard D, Anglicheau D, Canaud G, Souberbielle JC, Kreis H, Noël LH, Friedlander G, Elie C, Legendre C, Prié D. Vitamin D status and outcomes after renal transplantation. J Am Soc Nephrol 2013 Apr 24(5):831-41.
- KDOQI Work Group. KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. Executive summary. Am J Kidney Dis. 2009 Mar 53(3 Suppl 2):S11-104.
- Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, Green MD, Jha V, Josephson MA, Kiberd BA, Kreis HA, McDonald RA, Newmann JM, Obrador GT, Vincenti FG, Cheung M, Earley A, Raman G, Abariga S, Wagner M, Balk EM; Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients: A summary. Kidney Int 2010 Feb;77(4):299-311.
- Bacchetta J, Ranchin B, Demède D, Allard L. The consequences of pediatric renal transplantation on bone metabolism and growth.Curr Opin Organ Transplant. 2013 Aug 29 [Epub ahead of print].
- Mehls O, Fine RN. Growth hormone treatment after renal transplantation: A promising but underused chance to improve growth. Pediatr Nephrol 2013;28:1–4.
- Cochat P, Harambat J. Maximizing growth in children after renal transplantation. Transplantation 2009; 88:1321–1322.
- Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoidinduced osteoporosis: Pathophysiology and therapy. Osteoporos Int (2007) 18:1319–1328.
- Satterwhite T, Chua M-S, Hsieh S-C, Chang S, Scandling J, Salvatierra O, Sarwal MM. Increased expression of cytotoxic effector molecules: Different interpretations for steroid-based and steroid-free immunosuppression. Pediatr Transplantation 2003: 7: 53–58.
- Hayashi K,Yamaguchi T, Yano S, Kanazawa I, Yamauchi M,Yamamoto M, Sugimoto T. BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: Potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 2009 Feb 6;379(2):261-6.
- Wolf M, Molnar MZ, Amaral AP, et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011: 5: 956–966.
- Giannini S, D’angelo A, Carraro G, Antonello A, Di Landro, D, et al. Persistently increased bone turnover and low bone density in long-term survivors to kidney transplantation. Clin Nephrol 2001 Nov;56(5):353-63.
- Hamiwka LA, Hanna M, Midgley JP, Wade AW, Grisaru S. Areal and volumetric bone mineral density changes after renal transplantation in children: A longitudinal study. Transplant Proc 2008 Jun;40(5):1404-6.
- Unal A, Kocyigit I, Sipahioglu MH, Tokgoz B, Kavuncuoglu F, Oymak O, Utas C. Loss of Bone Mineral Density in Renal Transplantation Recipients. Transplant Proc 2010 Nov 42(9):3550-3.
- Almond MK, Kwan JTC Evans K, Cunningham J. Loss of Regional Bone Mineral Density in the First 12 Months following Renal Transplantation. Nephron 1994; 66(1): 52-7.
- Daniels MW, Wilson DM, Paguntalan HG, Hoffman AR, Bachrach LK. Bone mineral density in pediatric transplant recipients. Transplantation 2003 Aug 27;76(4):673-8.
- Govindarajan S, Khandelwal N, Sakhuja V, Jha V. Bone mineral density in patients with end-stage renal disease and its evolution after kidney transplantation. Indian J Nephrol 2011 Apr-Jun 21(2): 85–89.
- Epstein S. Post-transplantation bone disease: The role of immunosuppressive agents and the skeleton. J Bone Miner Res 1996; 11: 1–7.
- Leonard M B. Assessment of bone mass following renal transplantation in children. Pediatr Nephrol 2005; 20(3): 360-7.
- Grenda R, Karczmarewicz E, Rubik J, Matusik H, P³udowski P, Kiliszek M, Piskorski J. Bone mineral disease in children after renal transplantation in steroid-free and steroid-treated patients – A prospective study. Pediatr Transplantation 2011: 15:205– 213.
- Bhakta N, Marik J, Malekzadeh M, Gjertson D, Ettenger R. Can pediatric steroid-free renal transplantation improve growth and metabolic complications? Pediatr Transplantation 2008: 12: 854– 861.
- Barletta G-M, Kirk E, Gardner JJ, Rodriguez JF, Bursach SM, Bunchman TE. Rapid discontinuation of corticosteroids in pediatric renal transplantation. Pediatr Transplantation 2009:13:571–578.
- Grenda R, Webb NJA. Steroid minimization in pediatric renal transplantation: Early withdrawal or avoidance? Pediatr Transplantation 2010: 14:961–967.
- Delucchi A, Valenzuela M, Ferrario M, et al. Early steroid withdrawal in pediatric renal transplant on newer immunosuppressive drugs. Pediatr Transplant 2007: 11: 743– 748.
- Grenda R, Karczmarewicz E, Rubik J, Matusik H, P³udowski P, Kiliszek M, Piskorski J. Bone mineral disease in children after renal transplantation in steroid-free and steroid-treated patients – A prospective study. Pediatr Transplantation 2011: 15:205– 213.
- Movsowitz C, Epstein S, Fallon M et al. Cyclosporin-A in vivo produces severe osteopenia in the rat: Effect of dose and duration of administration. Endocrinology 1988; 123: 2571–2577.
- Cvetkovic M, Mann GN, Romero DF, Liang XG, Ma Y, Jee WS, Epstein S. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation.1994 Apr 27;57(8):1231-7.
- Kempe DS, Dërmaku-Sopjani M, Fröhlich H, Sopjani M, Umbach A, Puchchakayala G, Capasso A, Weiss F, Stübs M, Föller M, Lang F. Rapamycin-induced phosphaturia. Nephrol Dial Transplant 2010 Sep 25(9):2938-44.
- Alshayeb HM, Josephson MA, Sprague SM. CKD-mineral and bone disorder management in kidney transplant recipients. Am J Kidney Dis. 2013 Feb 61(2):310-25.
- Kalantar-Zadeh K, Molnar MZ, Kovesdy CP, Mucsi I, Bunnapradist S. Management of mineral and bone disorder after kidney transplantation. Curr Opin Nephrol Hypertens 2012 Jul 21(4):389-403.
- Derakhshan A, Behbahan AG, Lotfi M, Omrani GH, Fallahzadeh MH, Basiratnia M, Al-Hashemi GH. Bone mineral disorders in pediatric and adolescent renal transplant recipients. Pediatr Transplant 2011 Jun;15(4): 367-75. doi: 10.1111/j.1399-3046, 2011.01492. x. Epub 2011 Mar 23. PubMed PMID: 21429060.